NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for CHO-K1 Cells (Ovarian Adenocarcinoma Cells, CRL-9618)
- A liposome-based lipid formulation
Transfection Enhancer reagent provided with the kit
Produce higher level of recombinant protein expression with minimal disruption of normal cell function
Generate physiologically relevant data you can trust
Effective for plasmid DNA/siRNA co-transfection
Easy-to-use transfection protocol with reproducible results
- Download PowerPoint presentation for CHO-K1 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 92% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems CHO-K1 Transfection Protocol: [PDF]
Download MSDS: [PDF]
CHO-K1 Cell Line:
The CHO-K1 cell line was established using a subclone of the CHO cell line, which was originally established in 1957 from ovary tissue from an adult Chinese hamster (cricetulus griseus). This cell line requires the presence of proline for growth, but makes for a good transfection host. CHO-K1 cells are resistant to poliovirus 2, Button Willow virus, and modoc virus. These cells are useful in a variety of biomedical research applications related to molecular and cell biology.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into CHO-K1 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in CHO-K1 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into CHO-K1 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6450)
- 1.5 ml (Catalog #6451)
- 1.5 ml CRISPR (Catalog #2129)
- 8.0 ml (Catalog #7030)